Scientific Research
- Mazar AP. “Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy”
- Bruni et al. Vascular leaking, a pivotal and early pathogenetic event in systemic sclerosis: should the door be closed? Front Immunol. 2018; 9:2045. doi:10.3389/fimmu.2018.02045
- Napolitano et al., N-Formyl Peptide Receptors induce radical oxygen production in fibroblasts derived from systemic sclerosis by interacting with a cleaved form of Urokinase Receptor. Front Immunol. 2018; 9:574. doi:10.3389/fimmu.2018.00574
- Matucci-Cerinic et al., The “myth” of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event? Arthritis Res Ther. 2017;19(1):162. doi:10.1186/s13075-017-1370-5
- Prevete et al., Formyl Peptide Receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways. Oncoimmunology. 2017;6(4):e1293213. doi:10.1080/2162402X.2017.1293213
- Montuori et al., Urokinase Type Plasminogen Activator Receptor (uPAR) as a new therapeutic target in cancer. Transl Med UniSa. 2016;15:15-21.
- Rossi et al., The Urokinase/Urokinase receptor system in mast cells: effects of its functional interaction with fMLF receptors. Transl Med UniSa. 2016;15:34-41.
- Rossi et al., Upregulation of the N-Formyl Peptide Receptors in sclerodenna fibroblasts fosters the switch to myofibroblasts. J Immunol (2015) 194:5161-73.
- Prevete et al., Formyl Peptide Receptors at the interface of inflammation, angiogenesis and tumor growth. Pharmacol Res; (2015) 102:184-91.
- Rea et al., Discovery of new small molecules targeting the Vitronectin-binding site of the Urokinase receptor that block cancer cell invasion. Mol Cancer Ther (2013) 12:1402-16.